Systemic therapy for patients with BRAF‐mutated melanoma is currently based on two different approaches, either targeted therapy (BRAF and MEK inhibition) or immunotherapy (anti‐programmed death receptor (PD)‐1 therapy alone or combined with anti‐cytotoxic T lymphocyte antigen (CTLA)‐4 therapy), both in the adjuvant (except for combined immunotherapy) or metastatic setting. The gene discussed is BRAF; the disease is melanoma.